National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment

In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes. Insulin degludec (Tresiba?) is a new basal ultra-long-acting insulin analogue with a flat, stable gl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Gagik Radikovich Galstyan
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	diabetes mellitus glycaemic control basal insulin degludec hypoglycaemia cardiovascular safety Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/24b4ef9c9f704b85892f4bf526c0a719
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:24b4ef9c9f704b85892f4bf526c0a719
record_format	dspace
spelling	oai:doaj.org-article:24b4ef9c9f704b85892f4bf526c0a7192021-11-14T09:00:19ZNational advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment2072-03512072-037810.14341/DM20143129-133https://doaj.org/article/24b4ef9c9f704b85892f4bf526c0a7192014-10-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6698https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes. Insulin degludec (Tresiba?) is a new basal ultra-long-acting insulin analogue with a flat, stable glucose-lowering profile, ultra-long duration of action (>=42 h) and less within-patient day-to-day variability in glucose-lowering effect compared with currently available basal insulins. In the clinical trial programme, insulin degludec showed a similar glycaemic control compared with insulin glargine using the same insulin dose, but with a lower risk of hypoglycaemia and a greater flexibility in the time of dosing on a daily basis, when needed. Thus, the use of insulin degludec in routine clinical practice provides an effective and improved treatment for type 1 and 2 diabetes. The simple algorithm titration of insulin degludec offers the opportunity to personalise treatment regimens according to the needs of each patient.Gagik Radikovich GalstyanEndocrinology Research Centrearticlediabetes mellitusglycaemic controlbasal insulindegludechypoglycaemiacardiovascular safetyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 17, Iss 3, Pp 129-133 (2014)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus glycaemic control basal insulin degludec hypoglycaemia cardiovascular safety Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus glycaemic control basal insulin degludec hypoglycaemia cardiovascular safety Nutritional diseases. Deficiency diseases RC620-627 Gagik Radikovich Galstyan National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
description	In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes. Insulin degludec (Tresiba?) is a new basal ultra-long-acting insulin analogue with a flat, stable glucose-lowering profile, ultra-long duration of action (>=42 h) and less within-patient day-to-day variability in glucose-lowering effect compared with currently available basal insulins. In the clinical trial programme, insulin degludec showed a similar glycaemic control compared with insulin glargine using the same insulin dose, but with a lower risk of hypoglycaemia and a greater flexibility in the time of dosing on a daily basis, when needed. Thus, the use of insulin degludec in routine clinical practice provides an effective and improved treatment for type 1 and 2 diabetes. The simple algorithm titration of insulin degludec offers the opportunity to personalise treatment regimens according to the needs of each patient.
format	article
author	Gagik Radikovich Galstyan
author_facet	Gagik Radikovich Galstyan
author_sort	Gagik Radikovich Galstyan
title	National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
title_short	National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
title_full	National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
title_fullStr	National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
title_full_unstemmed	National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
title_sort	national advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
publisher	Endocrinology Research Centre
publishDate	2014
url	https://doaj.org/article/24b4ef9c9f704b85892f4bf526c0a719
work_keys_str_mv	AT gagikradikovichgalstyan nationaladvisoryboardondiabetesmellitusunsolvedissuesandnewopportunitiesfordiabetestreatment
_version_	1718429513261514752

National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment

Ejemplares similares